Table 3 Exploration of heterogeneity on the LDCT versus control for lung cancer mortality
Category | No. of estimates | Pooled RR (95% CI) | Heterogeneity I2 (%) |
|---|---|---|---|
Total | 9 | 0.83* (0.76–0.90) | 1 |
Subgroup analyses | |||
Type of control groups | |||
LDCT versus no screening | 7 | 0.78* (0.68–0.89) | 0 |
LDCT versus CXR | 2 | 0.94 (0.68–1.29) | 47 |
Quality of studies | |||
Moderate to high quality | 7 | 0.82* (0.73–0.91) | 7 |
Low quality | 2 | 0.87 (0.64–1.20) | 23 |
Sample size | |||
Smaller size (DANTE, DLCST, ITALUNG, LUSI, MILD, Yang 2018, LSS) | 7 | 0.87 (0.73–1.04) | 5 |
Larger size (NELSON, NLST) | 2 | 0.80* (0.71–0.91) | 13 |
Sex | |||
Male | 2 | 0.76* (0.63–0.93) | 0 |
Female | 2 | 0.52* (0.29–0.92) | 13 |
Sensitivity analysis | |||
Exclusion of the studies from Asia and ≦ 5 years of follow up | |||
Exclude Yang 2018 | 8 | 0.83* (0.76–0.91) | 1 |
Exclusion of studies in random manner | |||
Exclude DANTE | 8 | 0.82* (0.74–0.89) | 0 |
Exclude DLCST | 8 | 0.82* (0.75–0.90) | 1 |
Exclude ITALUNG | 8 | 0.83* (0.75–0.92) | 5 |
Exclude LUSI | 8 | 0.83* (0.75–0.92) | 8 |
Exclude MILD | 8 | 0.83 * (0.75–0.92) | 8 |
Exclude NELSON | 8 | 0.86* (0.77–0.95) | 0 |
Exclude LSS | 8 | 0.82* (0.75–0.89) | 0 |
Exclude NLST | 8 | 0.81* (0.70–0.93) | 7 |